Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Arwr save search
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 1.14%
H: 5.63%
C: -0.39%
treatment pharmaceuticals study
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Published: 2023-05-16 (Crawled : 12:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: -1.33%
H: 0.05%
C: -4.37%
treatment pharmaceuticals trial
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: -0.46%
H: 2.06%
C: -0.46%
treatment ongoing study phase 1
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Published: 2023-02-02 (Crawled : 13:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 1.3%
H: 3.52%
C: 3.52%
treatment fibrosis pharmaceuticals study phase 1
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial phase 1
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial therapeutics phase 1
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
Published: 2022-04-26 (Crawled : 12:20) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
treatment phase 2 hypercholesterolemia
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
Published: 2022-03-24 (Crawled : 12:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 0.9%
H: 2.48%
C: 2.44%
treatment clearance phase 1 disease
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Published: 2022-03-15 (Crawled : 12:30) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 1.89%
H: 2.65%
C: 0.87%
treatment clearance phase 1 phase 2
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2022-02-18 (Crawled : 13:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: -0.09%
H: 2.1%
C: -1.97%
treatment als disease media phase 1 phase 2 phase 3
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Published: 2022-01-12 (Crawled : 13:30) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 1.71%
H: 1.17%
C: -3.83%
phase 3 syndros treatment
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment liver
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: -0.69%
H: 1.61%
C: 0.11%
disease media treatment phase 1 phase 2 clearance
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Published: 2021-09-30 (Crawled : 12:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 1.24%
H: 3.54%
C: 1.71%
treatment phase 2 phase 2b
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.06%
C: -1.17%
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 1.95%
H: 1.82%
C: -1.98%
disease liver disease treatment fda therapy breakthrough therapy liver designation
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Published: 2021-07-06 (Crawled : 13:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: -3.19%
H: 3.74%
C: -2.98%
treatment phase 1 renal positive results phase 1b phase 2b cell carcinoma
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Published: 2021-06-30 (Crawled : 13:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: -0.6%
H: 4.07%
C: 2.23%
treatment phase 2 phase 2b
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 1.32%
H: 4.07%
C: -2.12%
treatment positive nash liver
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Published: 2021-06-03 (Crawled : 12:15) - biospace.com/
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 0.18%
H: 0.65%
C: 0.21%
treatment phase 2 phase 2b
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Published: 2021-04-28 (Crawled : 13:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.95%
H: 0.84%
C: 0.48%
ARWR | $24.02 -2.75% -2.83% 880K
|
Health Technology
|
| O: 0.01%
H: 2.92%
C: 1.92%
disease liver disease treatment fibrosis liver
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.